Gpi — M&A Activity 2025

Nov 13, 2025

{0}------------------------------------------------

PRESS RELEASE

GPI STRENGTHENS IN FRANCE: SUBSIDIARY EVOLUCARE ACQUIRES LOGIPREM-F, LEADER IN NEONATOLOGY SOFTWARE

Trento, 13 November 2025

GPI S.p.A. (GPI: IM), a leading company in software solutions and services supporting the digital transformation of healthcare, listed on the Euronext Milan – Tech Leaders market, announces that its French subsidiary Evolucare Investment SAS – which is jointly and severally liable – through its own subsidiary Evolucare Technologies SAS, has completed today the acquisition of 100% of the share capital of Logiprem-F SAS ("Logiprem-F"). Simultaneously, an 11% stake was transferred to Logiprem-F's top managers, bringing Evolucare Technologies' participation to 89% of the share capital.

Logiprem-F is a key player in prescription software for neonatal and pediatric intensive care units. The neonatology software adds further specialization to the Group's Critical Care software solutions dedicated to intensive care, operating rooms, and anesthesia.

Logiprem, France's leading SaaS platform for neonatal intensive care, was developed through a multidisciplinary approach involving physicians, pharmacists, nurses, and developers. The software is based on proprietary, continuously updated, drug and protocol databases, which have reduced prescription errors by a factor of 13 and saved time both in the prescribing process and in execution. The software is recognized in France as the market leader for reliability and safety in complex pediatric prescribing.

The business model ensures high visibility and stability, with a churn rate close to zero since its launch in 2016. Integration into Evolucare will strengthen the Gpi Group's Critical Care offering and support its expansion into key European markets.

In 2025, Logiprem-F operates with a workforce of approximately 40 FTEs and manages a solid customer base composed of over 90 hospitals, primarily in France, with initial expansion into Spain and Germany. Total Revenues in 2025 will stand at €4.7 million.

The transaction was structured based on a total Enterprise Value (100%) of 24 million euros, calculated on a 2025 forecasted EBITDA of approximately €1.4 million. It entails the acquisition of 89% of Logiprem-F's share capital on a debt-free, cash-free basis. The payment will comprise an initial cash consideration of 16 million euros, with variable adjustments (earn-out) linked to the operating and financial performance achieved by the Company in the 2025 and 2026 financial years. Logiprem-F's top managers will retain the remaining 11% of the share capital, with specific Put & Call agreements.

With this acquisition, GPI S.p.A. and its subsidiary Evolucare Technologies SAS become the leading software provider in Europe for the Critical Care sector.

{1}------------------------------------------------

GPI GROUP

Gpi's mission is to make the healthcare systems sustainable through their digitisation, so that everyone can receive high-quality care. Sustainability and social impact are the guiding principles and play a crucial role in the strategic and investment assessments of the Group, aware that the solutions and services provided to the community have an impact on the quality of life of individuals.

For over 35 years, driven by a patient-centric vision, Gpi has been working to support healthcare systems by providing the skills and innovative tools necessary to improve prevention and treatment processes. This is achieved through the strategic use of advanced software, technologies, and cutting-edge services.

The Group's strategy is designed to meet the evolving requirements of the constantly changing healthcare sector and to facilitate entry into international markets.

The unwavering commitment of its 7,600 employees and a customer base of more than 9,000 across 70 countries, yielded € 510 million in revenue, an EBITDA of € 105 million in 2024.

Gpi S.p.A. is listed on the Euronext Tech Leaders segment of Borsa Italiana, the Italian stock exchange.

ISIN ordinary shares: IT0005221517

This press release is also available at www.gpigroup.com and www.1info.it

CONTACTS

Investor Relations

GPI | Fabrizio Redavid, Lorenzo Giollo | investor.relations@gpi.it | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento

Media Relations

GPI | Enrico Orfano| media.relations@gpi.it | T: +390461381515 | Via Ragazzi del '99, 13 - 38123 Trento

Specialist

Banca Akros | Bruno Mestice | bruno.mestice@bancaakros.it | T. +3902434441 | Viale Eginardo, 29 – 20149 Milan